دورية أكاديمية
أعرض في EDS

Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension.

التفاصيل البيبلوغرافية
العنوان: Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension.
المؤلفون: Ørbæk Andersen M; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Diederichsen SZ; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Svendsen JH; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC), Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagnen, Denmark., Carlsen J; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark joern.carlsen@regionh.dk.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagnen, Denmark.
المصدر: Open heart [Open Heart] 2024 May 07; Vol. 11 (1). Date of Electronic Publication: 2024 May 07.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101631219 Publication Model: Electronic Cited Medium: Print ISSN: 2053-3624 (Print) Linking ISSN: 20533624 NLM ISO Abbreviation: Open Heart Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BMJ Publishing Group
مواضيع طبية MeSH: Heart Rate*/physiology , Hypertension, Pulmonary*/physiopathology , Hypertension, Pulmonary*/diagnosis , Hypertension, Pulmonary*/therapy, Humans ; Female ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Endarterectomy/methods ; Aged ; Antihypertensive Agents/therapeutic use ; Time Factors ; Angioplasty, Balloon/methods ; Adult ; Lung Transplantation ; Electrocardiography, Ambulatory/methods ; Pulmonary Artery/physiopathology
مستخلص: Background: The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. There is increasing evidence to support the role of early intervention and treatment in affecting clinical outcomes in PH.
Objectives: To assess treatment effects before and after the escalation of specific PH treatments using continuous heart monitoring with a Reveal LINQ loop recorder.
Methods: Patients were compared before and after treatment escalation. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation. Specifically, changes in heart rate variability (HRV), heart rate (HR) and physical activity were assessed.
Results: In this prospective study, 41 patients (27 with PAH and 14 with chronic thromboembolic pulmonary hypertension (CTEPH)) were enrolled. Among them, 15 (36.6%) patients underwent PH treatment escalation. Prior to escalation, patients were monitored for a median of 100 (range: 68-100) days and after therapy escalation for a median duration of 165 (range: 89-308) days. In the escalation group, there was a significant increase in HRV, physical activity indexed by daytime HR and a significant decrease in nighttime HR assessed at baseline and after treatment escalation in both the PAH and CTEPH groups. This was paralleled by significant improvements in WHO functional class, 6-min walking distance and N-terminal pro-b-type natriuretic peptide.
Conclusions: This is the first study to demonstrate an association between specific PH therapies and changes in HRV, HR nighttime and physical activity. This indicates the potential of continuous monitoring in the evaluation of treatment effects in PH.
Competing Interests: Competing interests: Mads Ørbæk Andersen has nothing to declare. Søren Zöga Diederichsen has received consultancy fees from Bristol Myers Squibb/Pfizer, Vital Beats and Acesion Pharma, speaker fees from Bristol Myers Squibb, and travel grants from Abbott. Jesper Hastrup Svendsen is a member of an advisory board for Medtronic and has received speaker fees and research grants from Medtronic. Jørn Carlsen is a member of an advisory board for Merck and has received institutional research grants and institutional speaker fees.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: N Engl J Med. 2015 Dec 24;373(26):2522-33. (PMID: 26699168)
J Clin Med. 2023 Jan 17;12(3):. (PMID: 36769403)
Eur Respir Rev. 2020 May 15;29(156):. (PMID: 32414745)
Am Heart J. 2007 Jun;153(6):1037-47. (PMID: 17540207)
Anatol J Cardiol. 2015 Mar;15(3):249-54. (PMID: 25880178)
Respir Res. 2017 Dec 4;18(1):201. (PMID: 29202826)
Vasc Health Risk Manag. 2023 Mar 03;19:103-126. (PMID: 36895278)
Open Heart. 2023 Jun;10(1):. (PMID: 37385731)
Circulation. 2012 Jul 17;126(3):349-56. (PMID: 22696079)
Front Pediatr. 2015 Jul 07;3:63. (PMID: 26217650)
Eur Heart J. 2022 Oct 11;43(38):3618-3731. (PMID: 36017548)
Pharmaceuticals (Basel). 2022 Oct 17;15(10):. (PMID: 36297387)
Clinicoecon Outcomes Res. 2017 Nov 24;9:731-739. (PMID: 29200882)
J Am Coll Cardiol. 2012 Sep 25;60(13):1192-201. (PMID: 22995024)
Circulation. 2018 Feb 27;137(9):925-927. (PMID: 29483171)
Am J Respir Crit Care Med. 2012 Sep 1;186(5):396-7. (PMID: 22942342)
Int J Cardiovasc Imaging. 2018 May;34(5):777-786. (PMID: 29168055)
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1472-1487. (PMID: 33861689)
World J Cardiol. 2015 Apr 26;7(4):204-14. (PMID: 25914789)
Eur Respir Rev. 2012 Mar 1;21(123):40-7. (PMID: 22379173)
Eur Respir Rev. 2012 Dec 1;21(126):313-20. (PMID: 23204119)
J Cardiothorac Surg. 2022 Aug 29;17(1):216. (PMID: 36038916)
J Am Heart Assoc. 2018 Sep 18;7(18):e009729. (PMID: 30371195)
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. (PMID: 20620859)
N Engl J Med. 2023 Mar 23;388(12):1111-1125. (PMID: 36947468)
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S1-S2. (PMID: 19555852)
فهرسة مساهمة: Keywords: defibrillators, implantable; hypertension, pulmonary; pulmonary arterial hypertension
المشرفين على المادة: 0 (Antihypertensive Agents)
تواريخ الأحداث: Date Created: 20240508 Date Completed: 20240508 Latest Revision: 20240512
رمز التحديث: 20240512
مُعرف محوري في PubMed: PMC11086549
DOI: 10.1136/openhrt-2024-002710
PMID: 38719497
قاعدة البيانات: MEDLINE
الوصف
تدمد:2053-3624
DOI:10.1136/openhrt-2024-002710